
Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.

John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.

Robert L. Stamper, MD, discusses the findings of a study analyzing the effects of corneal mechanics on IOP, presented during the virtual Glaucoma 360 meeting.

During the 2021 Glaucoma 360 meeting, Ruth D. Williams, MD, speaks on the highlights and key findings from the EAGLE study, which showed clear lens extraction surgery may be a better initial treatment for some glaucoma patients.

Andrew Iwach, MD, and Adrienne Graves, PhD, co-founders of Glaucoma 360, preview what attendees will experience at the 2021 version of the CME/CE Symposia, Annual Gala, and New Horizons Forum.






















From patient care and treating glaucoma to the ongoing pandemic, ophthalmologists share the most pressing thoughts of concern leaving them awake at night.

Joshua Mali, MD, speaks on his annual top 5 predictions in ophthalmology for what's to come in 2021.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.